Table 3. Patient characteristics at admission according to survival or death (n = 305).
| Parameters | All Patients MD [Q1;Q3] or n, (range: min-max) or (% of all patients) |
Survivals MD [Q1;Q3] or n, (range: min—max) or (% of Survivals) |
Deaths MD [Q1;Q3], (range: min—max) or (% of Deaths) |
P Significance |
|---|---|---|---|---|
| Patients | 305 | 213 | 92 | NA |
| Age (y) | 60 [49;72] (range: 18–90) | 58 [45;69], (range: 18–89) | 63 [54;73], (range: 21–90) | 0.0033* |
| Sex, n(%) | ♂ 184(60.3%) | ♂128 (60.1%) | ♂ 56 (60.8%) | 1.0000° |
| ♀ 121(39.7%) | ♀85 (39.9%) | ♀ 36 (39.1%) | ||
| Body Mass Index (kg/m2) | 25.7[22.1;29.0](range: 13.6–70.3) | 25.4 [21.8; 28.9], (range: 13.6–48.2) | 25.7 [23.3; 29.3], (range: 13.6–70.3) | 0.4880* |
| Chronic diseases / Co-morbidities | ||||
| CKD | 131(43.0%) | 86 (40.4%) | 45 (48.9%) | 0.2075° |
| Cirrhosis § | 68 (22.3%) | 30 (14.2%) | 38 (41.8%) | <0.0001° |
| Solid Organ Transplantation | 55 (18.0%) | 41 (19.3%) | 14 (15.2%) | 0.5164° |
| Cancer & Cancer Therapy§ | 15 (4.9%) | 10 (4.7%) | 5 (5.5%) | 0.7768° |
| Chronic Heart Failure (NYHA IV) § | 10 (3.3%) | 4 (1.9%) | 6 (6.6%) | 0.0711° |
| Hematological Cancer § | 6 (2.0%) | 4 (1.9%) | 2 (2.2%) | 1.0000° |
| AIDS § | 4 (1.3%) | 3 (1.4%) | 1 (1.1%) | 1.0000° |
| Acute conditions | ||||
| AKI | 97 (31.8%) | 57 (26.8%) | 40 (43.5%) | 0.0049° |
| Cardiac Arrhythmias § | 52 (17.1%) | 35 (16.4%) | 17 (18.7%) | 0.6218° |
| Liver Failure § | 50 (16.5%) | 19 (8.9%) | 31 (34.1%) | <0.0001° |
| Sepsis | 43 (14.1%) | 16 (7.5%) | 27 (29.4%) | <0.0001° |
| Nosocomial Infection § | 26 (8.5%) | 16 (7.5%) | 10 (10.9%) | 0.3732° |
| Vigilance Disturbances § | 26 (8.5%) | 17 (8.0%) | 9 (9.9%) | 0.6550° |
| Respiratory Insufficiency with NIV | 17 (5.6%) | 12 (5.8%) | 5 (5.5%) | 1.0000° |
| Septic Shock § | 15 (4.9%) | 11(5.2%) | 4(4.4%) | 1.0000° |
| Digestive Illnesses (e.g. severe pancreatitis, acute abdomen) § | 11 (3.6%) | 10 (4.7%) | 1 (1.1%) | 0.1832° |
| Gastrointestinal Bleedings | 10 (3.3%) | 9 (4.2%) | 1 (1.1%) | 0.2918° |
| Focal Neurological Deficits § | 3 (1.0%) | 3 (1.4%) | 0 | 0.5568° |
| Therapeutic interventions at admission | ||||
| Vasoactive Drugs § | 188 (61.6%) | 133 (62.7%) | 55 (59.8%) | 0.7000° |
| Hemodialysis | 70 (23.0%) | 41 (19.3%) | 29 (31.5%) | 0.0257° |
| NIV | 17 (5.6%) | 12 (5.8%) | 5 (5.5%) | 1.0000° |
| Stay in the ImCU (d) | 6[3;14], (range: 0–115) | 6 [3; 14], (range: 0–115) | 7 [3; 22], (range: 1–67) | 0.1197* |
| SAPS 2 | 30 [22;39], (range: 6–69) | 27 [19; 36], (range: 6–65) | 37.5 [27.5; 47.0], (range: 13–69) | <0.0001* |
| SAPS 2 predicted mortality | 10.6% [4.7;23.0], (range: 0.5–80.6) | 7.9% [3.3; 18.1], (range: 0.5–76.9) | 20.5% [8.4; 39.2], (range: 1.5–82.6) | <0.0001* |
| SAPS 3 | 55[46;64], (range: 24–90) | 51 [44; 59], (range: 24–88) | 63 [57; 71], (range: 39–90) | <0.0001* |
| SAPS 3 predicted mortality | 26.0% [12.0;44.0], (range: 1.0–85.0) | 19.0% [10.0; 34.0], (range: 1.0–83.0) | 42.0% [30.0; 58.0], (range: 6.0–85.0) | <0.0001* |
MD = median, Q1 = first quartile, Q3 = third quartile, n = count, CKD = chronic kidney disease, AKI = acute kidney injury, NIV = non-invasive ventilation
§ = part of the SAPS 2 or SAPS 3 scoring system
NA = not applicable
* = Mann-Whitney U test
° = Fisher’s exact test